Aeglea Bio Therapeutics (NASDAQ:AGLE) Issues Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Aeglea Bio Therapeutics (NASDAQ:AGLE) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.07), Bloomberg Earnings reports.

Shares of Aeglea Bio Therapeutics stock traded down $0.11 during trading hours on Wednesday, reaching $7.80. 6,724 shares of the company’s stock were exchanged, compared to its average volume of 155,700. Aeglea Bio Therapeutics has a 1 year low of $5.99 and a 1 year high of $11.16. The stock has a market capitalization of $221.42 million, a P/E ratio of -3.69 and a beta of 1.02. The firm has a fifty day moving average price of $7.17.

Several equities research analysts recently commented on the stock. BidaskClub raised shares of Aeglea Bio Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 2nd. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Aeglea Bio Therapeutics in a report on Monday, June 3rd. Finally, ValuEngine raised shares of Aeglea Bio Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $14.33.

In other Aeglea Bio Therapeutics news, CEO Anthony G. Quinn bought 6,218 shares of the company’s stock in a transaction dated Friday, May 17th. The stock was acquired at an average price of $6.65 per share, with a total value of $41,349.70. Following the completion of the acquisition, the chief executive officer now directly owns 277,152 shares of the company’s stock, valued at $1,843,060.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Anthony G. Quinn bought 12,217 shares of the company’s stock in a transaction dated Wednesday, June 12th. The shares were acquired at an average cost of $6.11 per share, with a total value of $74,645.87. Following the acquisition, the chief executive officer now directly owns 333,955 shares of the company’s stock, valued at $2,040,465.05. The disclosure for this purchase can be found here. Insiders have bought 92,177 shares of company stock valued at $593,817 in the last ninety days. Insiders own 12.60% of the company’s stock.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Further Reading: Is the QQQ ETF safe?

Earnings History for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.